| A. For all patient populations with evidence of preceding GAS infection | |
|---|---|
| Diagnosis: initial ARF | 2 Major manifestations or 1 major plus 2 minor manifestations |
| Diagnosis: recurrent ARF | 2 Major or 1 major and 2 minor or 3 minor |
| B. Major criteria | |
| Low-risk populations* | Moderate- and high-risk populations |
| Carditis† · Clinical and/or subclinical | Carditis · Clinical and/or subclinical |
| Arthritis · Polyarthritis only | Arthritis · Monoarthritis or polyarthritis · Polyarthralgia‡ |
| Chorea | Chorea |
| Erythema marginatum | Erythema marginatum |
| Subcutaneous nodules | Subcutaneous nodules |
| C. Minor criteria | |
| Low-risk populations* | Moderate- and high-risk populations |
| Polyarthralgia | Monoarthralgia |
| Fever (≥38.5°C) | Fever (≥38°C) |
| ESR ≥60 mm in the first hour and/or CRP ≥3.0 mg/dL§ | ESR ≥30 mm/h and/or CRP ≥3.0 mg/dL§ |
| Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion) | Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion) |
*Low-risk populations are those with ARF incidence ≤2 per 100 000 school-aged children or all-age rheumatic heart disease prevalence of ≤1 per 1000 population per year.
†Subclinical carditis indicates echocardiographic valvulitis as defined in Table 3.
‡Polyarthralgia should only be considered as a major manifestation in moderate- to high-risk populations after exclusion of other causes. Erythema marginatum and subcutaneous nodules are rarely "stand-alone" major criteria. Additionally, joint manifestations can only be considered in either the major or minor categories but not both in the same patient.
§CRP value must be greater than upper limit of normal for laboratory. Also, because ESR may evolve during the course of ARF, peak ESR values should be used. Our note: 3.0 mg/dL is 30 mg/L.
WHO 2024 Table 1 differs: it prints Monoarthritis and Fever (≥38.5 °C) in the moderate- and high-risk minor column.
| Pathological mitral regurgitation (all 4 criteria met) | Pathological aortic regurgitation (all 4 criteria met) |
|---|---|
| Seen in at least 2 views | Seen in at least 2 views |
| Jet length ≥2 cm in at least 1 view | Jet length ≥1 cm in at least 1 view |
| Peak velocity >3 m/s | Peak velocity >3 m/s |
| Pansystolic jet in at least 1 envelope | Pan diastolic jet in at least 1 envelope |
Loading conditions should be accounted for at time of echocardiography/Doppler assessment.
| Class | Recommendation | LOE |
|---|---|---|
| IIb | Reliable past history of ARF or established RHD, documented GAS infection: the recurrent row may be sufficient for a presumptive diagnosis. | C |
| I | Minor manifestations alone: exclude other more likely causes first. | C |
| IIa | "Possible" ARF, genuine uncertainty: reasonable to consider offering 12 months of secondary prophylaxis, then reevaluate with history, examination and repeat echo. | C |
| Class | Recommendation (Gewitz 2015, paraphrased) | LOE |
|---|---|---|
| IIa | Reasonable to consider individuals low risk if they come from a setting or population known to have low rates of ARF or RHD. | C |
| IIa | With reliable epidemiological data, reasonable to define low risk as ARF incidence <2 per 100 000 school-aged children (usually 5–14 years old) per year or all-age RHD prevalence ≤1 per 1000 population per year. | C |
| I | Children not clearly from a low-risk population are at moderate to high risk depending on their reference population. | C |
| I | Echo with Doppler in all confirmed and suspected ARF. | B |
| IIa | Reasonable to consider serial echo/Doppler in any patient with diagnosed or suspected ARF, even without documented carditis at diagnosis. | C |
| I | Echo/Doppler, strictly applying the findings, to assess for carditis without auscultatory findings, particularly in moderate- to high-risk populations and when ARF is considered likely. | B |
| I | Echo/Doppler findings not consistent with carditis should exclude it in a patient with a murmur otherwise thought to indicate rheumatic carditis. | B |
| I | Consider monoarthritis part of the ARF spectrum only in moderate- to high-risk populations. | C |
| IIb | Polyarthralgia as a major manifestation: only for moderate- or high-incidence populations, after careful consideration and exclusion of other causes such as autoimmune, viral or reactive arthropathies. | C |
| I | Each of the three streptococcal evidence rows in the checklist. | B |
| IIa | Recurrent symptoms (particularly joints) despite adherent prophylaxis, no serological evidence of GAS infection and no echo evidence of valvulitis: reasonable to conclude they are not likely ARF; stopping prophylaxis may be appropriate. | C |
Adapted from Gewitz 2015, Figure, as corrected in 2020. Printed note: B, C, and D require evidence of GAS infection. *Subclinical carditis can be considered.
| Panel | Path | Box |
|---|---|---|
| A. Chorea | "Clinical" (our reading: clinical carditis): Yes | ARF diagnosed |
| A. Chorea | "Clinical": No; Echo Doppler Subclinical carditis: Yes | ARF diagnosed |
| A. Chorea | "Clinical": No; Echo Doppler Subclinical carditis: No; Rule out all else | ARF diagnosed |
| B. Arthritis | Clinical carditis or subclinical (echo Doppler) | ARF diagnosed |
| B. Arthritis | No carditis (neg echo Doppler); 2 minor criteria or another major criterion | ARF diagnosed |
| B. Arthritis | No carditis (neg echo Doppler); No criteria | Alt Diagnosis |
| C. Clinical Carditis | Echo confirms; One minor only | Probable ARF. Repeat echo at 14-21 days |
| C. Clinical Carditis | Echo confirms; Another major criterion or 2 minor criteria | ARF diagnosed |
| C. Clinical Carditis | Negative Echo | Alternate diagnosis |
| D. Subcutaneous Nodules Or Erythema Marginatum | Other major* or 2 minor | ARF diagnosed |
| D. Subcutaneous Nodules Or Erythema Marginatum | No major and /or 1 minor | Consider alternative diagnosis |
Tables 3 and 4, as printed in Gerber 2009 (endorsed by the AAP).
| Class | Agent, dose, mode | LOE |
|---|---|---|
| I | Benzathine penicillin G, intramuscular: 600 000 U for children ≤27 kg (60 lb), 1 200 000 U for those >27 kg (60 lb) every 4 wk† | A |
| I | Penicillin V, oral: 250 mg twice daily | B |
†Every 3 weeks where incidence is particularly high (Class I, LOE A). United States: only for recurrent ARF despite adherence to every 4 weeks (Class I, LOE C).
Sulfonamides are contraindicated in late pregnancy. Macrolides, and to a much lesser extent azalides, can prolong the QT interval. Macrolides should not be taken with inhibitors of cytochrome P-450 3A (Gerber 2009, p. 1548).
| Class | Agent, dose, mode | LOE |
|---|---|---|
| I | Penicillin allergy: sulfadiazine, oral: 0.5 g once daily for patients ≤27 kg (60 lb), 1.0 g once daily for patients >27 kg (60 lb) | B |
| I | Allergic to penicillin and sulfadiazine: macrolide or azalide, oral. Dose printed as "Variable". | C |
Gerber 2009, p. 1548: sulfisoxazole is acceptable at the same dose (Class IIa, LOE C). Allergic to both penicillin and sulfisoxazole: erythromycin or clarithromycin, or azithromycin (Class I, LOE C). "There are no published data about the use of other penicillins, macrolides, azalides, or cephalosporins for the secondary prevention of rheumatic fever." Table 4 words the last row as penicillin and sulfadiazine.
| Class | Category and duration | LOE |
|---|---|---|
| I | Rheumatic fever with carditis and residual heart disease (persistent valvular disease*): 10 years or until 40 years of age (whichever is longer), sometimes lifelong prophylaxis | C |
| I | Rheumatic fever with carditis but no residual heart disease (no valvular disease*): 10 years or until 21 years of age (whichever is longer) | C |
| I | Rheumatic fever without carditis: 5 years or until 21 years of age (whichever is longer) | C |
*Clinical or echocardiographic evidence.
Severe RHD (AHA 2022 advisory). Severe aortic insufficiency, severe mitral stenosis, severe aortic stenosis, Ventricular dysfunction (EF <50%) or Severe symptoms (NYHA class III or IV): oral prophylaxis, if reliably available and affordable, should be strongly considered (preferably penicillin, unless contraindicated). Oral is "unequivocally inferior", and this departs from AHA 2009's text. WHO 2024: may be considered. Available evidence and expert opinion; not split by age. Severity by the ACC/AHA classification Adult
The AHA 2015 criteria as printed, with a checklist